BrainStorm Cell Therapeutics Presenting at Multiple Upcoming Conferences

BrainStorm Cell Therapeutics Presenting at Multiple Upcoming Conferences 
NEW YORK, NY and PETACH TIKVAH, ISRAEL -- (Marketwired) -- 05/19/14
--  BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer
of adult stem cell technologies for neurodegenerative diseases,
announced today that it is presenting at the following scientific and
industry conferences this month.  
MIXiii Biomed Israel Innovation Conference
 Mr. Chaim Lebovits,
BrainStorm's President, will present at the MIXiii Biomed Israel
Innovation Conference organized by the Israel Advanced Technologies
Industries, May 20-22 in Tel Aviv. Mr. Lebovits will participate in a
panel discussion entitled "Deal Making with Academy" on May 20th at
Joint Congress of European Neurology 
 Professor Dimitrios Karussis,
Principal Investigator of BrainStorm's clinical trials at Jerusalem's
Hadassah Medical Center, will present at the Joint Congress of
European Neurology, May 31-June 3 in Istanbul, Turkey. Prof.
Karussis' oral presentation, entitled "Analysis of patients with
amyotrophic lateral sclerosis (ALS) treated with autologous
differentiated mesenchymal stem cells: a phase I/II and IIa clinical
trial" will be in the Motor Neurone Diseases Session on June 1st,
16:45 - 18:15.  
Israstem 2014
 Dr. Yael Gothelf, BrainStorm's VP Scientific and
Regulatory Affairs, will present at the Israstem 2014 Conference,
June 10-11 in Ramat Gan, Israel. Dr. Gothelf's oral presentation,
entitled "Clinical Trials with Autologous Bone Marrow-Derived
Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in
Patients with Amyotrophic Lateral Sclerosis (ALS)," will be on June
11th at 11:00 a.m. 
About BrainStorm Cell Therapeutics, Inc.
 BrainStorm Cell
Therapeutics Inc. is a biotechnology company engaged in the
development of first-of-its-kind adult stem cell therapies derived
from autologous bone marrow cells for the treatment of
neurodegenerative diseases. The Company holds the rights to develop
and commercialize its NurOwn technology through an exclusive,
worldwide licensing agreement with Ramot, the technology transfer
company of Tel Aviv University. For more information, visit the
company's website at  
Safe Harbor Statement
 Statements in this announcement other than
historical data and information constitute "forward-looking
statements" and involve risks and uncertainties that could cause
BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may", "should", "would",
"could", "will", "expect", "likely", "believe", "plan", "estimate",
"predict", "potential", and similar terms and phrases are intended to
identify these forward-looking statements. The potential risks and
uncertainties include, without limitation, risks associated with
BrainStorm's limited operating history, history of losses; minimal
working capital, dependence on its license to Ramot's technology;
ability to adequately protect the technology; dependence on key
executives and on its scientific consultants; ability to obtain
required regulatory approvals; and other factors detailed in
BrainStorm's annual report on Form 10-K and quarterly reports on Form
10-Q available at These factors should be
considered carefully, and readers should not place undue reliance on
BrainStorm's forward-looking statements. The forward-looking
statements contained in this press release are based on the beliefs,
expectations and opinions of management as of the date of this press
release. We do not assume any obligation to update forward-looking
statements to reflect actual results or assumptions if circumstances
or management's beliefs, expectations or opinions should change,
unless otherwise required by law. Although we believe that the
expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity,
performance or achievements. 
BrainStorm Cell Therapeutics Inc. 
Mr. Chaim Lebovits
Phone: +972-3-923-6384  
US Investor Contact
LifeSci Advisors, LLC
Michael Rice
Phone: 646-597-6979 
Press spacebar to pause and continue. Press esc to stop.